Tokyo Tape
Sign in
← PeptiDream

Half-year report · HY

4587.TEDINET S100YVU6
Period2026-01-01 → 2026-06-30
Filed2026-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥9.2bn2026-01-01 → 2026-06-30Cons.Revenue IFRS
Revenue¥18.5bn2025-01-01 → 2025-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥8.5bn2025-01-01 → 2025-06-30Cons.Revenue IFRS
Operating income−¥2.5bn2026-01-01 → 2026-06-30Cons.Operating profit loss IFRS
Operating income−¥2.6bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Profit before tax−¥2.7bn2026-01-01 → 2026-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥5.3bn2025-01-01 → 2025-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥2.9bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥2.0bn2026-01-01 → 2026-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥3.7bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥2.0bn2026-01-01 → 2026-06-30Cons.Profit loss IFRS
Net income−¥3.7bn2025-01-01 → 2025-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Total assets¥72.2bnat 2026-06-30Cons.Assets IFRS
Total assets¥77.0bnat 2025-12-31Cons.Assets IFRS
Total assets¥78.5bnat 2025-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥23.7bnat 2026-06-30Cons.Liabilities IFRS
Total liabilities¥25.5bnat 2025-12-31Cons.Liabilities IFRS
Net assets / equity¥48.6bnat 2026-06-30Cons.Equity IFRS
Net assets / equity¥51.5bnat 2025-12-31Cons.Equity IFRS
Net assets / equity¥53.7bnat 2025-06-30Cons.Equity IFRS
Net assets / equity¥56.8bnat 2024-12-31vCons.Equity IFRS
Equity (owners)¥48.6bnat 2026-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥51.5bnat 2025-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥53.7bnat 2025-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥23.6bnat 2026-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥28.7bnat 2025-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥33.3bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥48.1bnat 2024-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.8bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥13.3bn2025-01-01 → 2025-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥11.0bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥614m2026-01-01 → 2026-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.1bn2025-01-01 → 2025-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.7bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥4.1bn2025-01-01 → 2025-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥2.5bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-15.512026-01-01 → 2026-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-28.992025-01-01 → 2025-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-16.42025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-15.512026-01-01 → 2026-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-28.992025-01-01 → 2025-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-16.42025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio67.2%at 2026-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.9%at 2025-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.3%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2026-01-01 → 2026-06-30−¥512m
Reconciling Itemsreconcilingrevenue intersegment2026-01-01 → 2026-06-30−¥512m
Drug Discovery And Development Businessreportable segmentrevenue2026-01-01 → 2026-06-30¥1.2bn
Drug Discovery And Development Businessreportable segmentrevenue external2026-01-01 → 2026-06-30¥1.2bn
Drug Discovery And Development Businessreportable segmentsegment profit2026-01-01 → 2026-06-30−¥2.7bn
Radiopharmaceuticals Businessreportable segmentrevenue2026-01-01 → 2026-06-30¥8.5bn
Radiopharmaceuticals Businessreportable segmentrevenue external2026-01-01 → 2026-06-30¥8.0bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥512m
Radiopharmaceuticals Businessreportable segmentsegment profit2026-01-01 → 2026-06-30¥242m
—segment totalrevenue2026-01-01 → 2026-06-30¥9.7bn
—segment totalrevenue external2026-01-01 → 2026-06-30¥9.2bn
—segment totalrevenue intersegment2026-01-01 → 2026-06-30¥512m
—segment totalsegment profit2026-01-01 → 2026-06-30−¥2.5bn
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥453m
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥453m
Drug Discovery And Development Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥761m
Drug Discovery And Development Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥761m
Drug Discovery And Development Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥3.0bn
Radiopharmaceuticals Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥8.2bn
Radiopharmaceuticals Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥7.8bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥453m
Radiopharmaceuticals Businessreportable segmentsegment profit2025-01-01 → 2025-06-30¥436m
—segment totalrevenue2025-01-01 → 2025-06-30¥9.0bn
—segment totalrevenue external2025-01-01 → 2025-06-30¥8.5bn
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥453m
—segment totalsegment profit2025-01-01 → 2025-06-30−¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 571
ItemContextValueUnit
Inventories ca IFRSPrior1YearInstant3190567000JPY
Inventories ca IFRSInterimInstant3677096000JPY
Income taxes receivable ca IFRSPrior1YearInstant22909000JPY
Income taxes receivable ca IFRSInterimInstant10545000JPY
Other current assets ca IFRSPrior1YearInstant1149851000JPY
Other current assets ca IFRSInterimInstant1278867000JPY
Current assets IFRSPrior1YearInstant38919826000JPY
Current assets IFRSInterimInstant33072781000JPY
Property plant and equipment IFRSPrior1YearInstant18929282000JPY
Property plant and equipment IFRSInterimInstant19344417000JPY
Goodwill IFRSPrior1YearInstant8370677000JPY
Goodwill IFRSInterimInstant8370677000JPY
Intangible assets IFRSPrior1YearInstant2016747000JPY
Intangible assets IFRSInterimInstant1955087000JPY
Investments accounted for using equity method IFRSPrior1YearInstant23567000JPY
Investments accounted for using equity method IFRSInterimInstant22243000JPY
Other financial assets nca IFRSPrior1YearInstant2108710000JPY
Other financial assets nca IFRSInterimInstant2094669000JPY
Deferred tax assets IFRSPrior1YearInstant6571301000JPY
Deferred tax assets IFRSInterimInstant7285413000JPY
Other non current assets nca IFRSPrior1YearInstant93075000JPY
Other non current assets nca IFRSInterimInstant80634000JPY
Non current assets IFRSPrior1YearInstant38113361000JPY
Non current assets IFRSInterimInstant39153143000JPY
Assets IFRSPrior1YearInstant77033187000JPY
Assets IFRSInterimInstant72225925000JPY
Trade and other payables cl IFRSPrior1YearInstant4253389000JPY
Trade and other payables cl IFRSInterimInstant3482382000JPY
Borrowings cl IFRSPrior1YearInstant17041512000JPY
Borrowings cl IFRSInterimInstant2612678000JPY
Other financial liabilities cl IFRSPrior1YearInstant461542000JPY
Other financial liabilities cl IFRSInterimInstant591342000JPY
Income taxes payable cl IFRSPrior1YearInstant－JPY
Income taxes payable cl IFRSInterimInstant40458000JPY
Provisions cl IFRSPrior1YearInstant37635000JPY
Provisions cl IFRSInterimInstant29867000JPY
Contract liabilities cl IFRSPrior1YearInstant994972000JPY
Contract liabilities cl IFRSInterimInstant593967000JPY
Other current liabilities cl IFRSPrior1YearInstant629489000JPY
Other current liabilities cl IFRSInterimInstant622510000JPY
Total current liabilities IFRSPrior1YearInstant23418542000JPY
Total current liabilities IFRSInterimInstant7973207000JPY
Borrowings ncl IFRSPrior1YearInstant－JPY
Borrowings ncl IFRSInterimInstant13076251000JPY
Other financial liabilities ncl IFRSPrior1YearInstant1949893000JPY
Other financial liabilities ncl IFRSInterimInstant2493917000JPY
Retirement benefit liability ncl IFRSPrior1YearInstant76136000JPY
Retirement benefit liability ncl IFRSInterimInstant69682000JPY
Provisions ncl IFRSPrior1YearInstant59692000JPY
Provisions ncl IFRSInterimInstant57058000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-12-31pass
balance sheet identityconsolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2026-01-01/2026-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2026-01-01/2026-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsconsolidated 2026-06-30pass